Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver

被引:0
|
作者
Kerr, T [1 ]
Palepu, A
Barnes, G
Walsh, J
Hogg, R
Montaner, J
Tyndall, M
Wood, E
机构
[1] Canadian HIV AIDS Legal Network, Montreal, PQ, Canada
[2] St Pauls Hosp, Brit Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada
[3] St Pauls Hosp, Ctr Hlth Evaluat & Outcomes Sci, Vancouver, BC V6Z 1Y6, Canada
[4] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada
[5] Univ Victoria, Dept Human & Social Dev, Victoria, BC, Canada
[6] Univ Victoria, Dept Educ Psychol & Leadership Studies, Victoria, BC, Canada
[7] Univ British Columbia, Dept Healthcare & Epidemiol, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Sub-optimal adherence to highly active antiretroviral therapy (HAART) among injection drug users (IDUs) is a significant concern. As such, there is an urgent need to identify psychosocial determinants of adherence that can be incorporated into interventions designed to promote optimal adherence. Objective: To identify psychosocial determinants of adherence to HAART, as well as self-reported reasons for missing doses of HAART among HIV-infected IDUs. Methods: We developed an eight-item adherence self-efficacy scale 'comprised of two sub-scales: adherence efficacy and self-regulatory efficacy. We examined correlates between adherence self-efficacy, outcome expectations, socio-demographic characteristics, drug use and risk behaviours, social support and HAART adherence among 108 HIV-infected participants in the Vancouver Injection Drug Users Study (VIDUS). Pharmacy-based adherence to HAART was obtained through a confidential record linkage to the province of British Columbia's HIV/AIDS Drug Treatment Program. Participants were defined as adherent if they picked-up 95% of their HAART prescriptions. Participants were also asked to indicate reasons for missing doses of HAART. Logistic regression was used to identify the factors independently associated with adherence to HAART. Results: Seventy-one (66%) HIV-infected IDUs were less than 95% adherent. Forgetting was the most frequently cited reason (27%) for missing doses of HAART. Factors independently associated with adherence to HAART included adherence efficacy expectations [OR=1.8 (95% CI: 1.0-3.1); P=0.039] and negative outcome expectations [OR=0.8 (95% CI: 0.7-0.9); P=0.027]. Conclusions: We found low rates of adherence to HAART among IDUs. Psychological constructs derived from self-efficacy theory are highly germane to the understanding of adherence behaviour, and interventions that address these constructs should be developed and tested among HIV-infected drug users.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 50 条
  • [1] Adherence and antiretroviral therapy in injection drug users
    Sherer, R
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06): : 567 - 568
  • [2] Highly active antiretroviral therapy for injection drug users: physician-recommended strategies for enhanced adherence
    Vassilev, ZP
    Hagan, H
    ANTIVIRAL THERAPY, 2004, 9 (03) : 461 - 461
  • [3] Time to initiating highly active antiretroviral therapy among HIV infected injection drug users
    Celentano, DD
    Galai, N
    Sethi, AK
    Shah, NG
    Strathdee, SA
    Vlahov, D
    Gallant, JE
    AIDS, 2001, 15 (13) : 1707 - 1715
  • [4] Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users
    Wood, E
    Montaner, JSG
    Yip, B
    Tyndall, MW
    Schechter, MT
    O'Shaughnessy, MV
    Hogg, RS
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2003, 169 (07) : 656 - 661
  • [5] Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting
    Krusi, Andrea
    Milloy, M-J
    Kerr, Thomas
    Zhang, Ruth
    Guillemi, Silvia
    Hogg, Robert
    Montaner, Julio
    Wood, Evan
    ANTIVIRAL THERAPY, 2010, 15 (05) : 789 - 796
  • [6] Mortality among urban drug users and the impact of highly active antiretroviral therapy
    Celentano, DD
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (06) : 873 - 874
  • [7] Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy
    Semba, RD
    Shah, N
    Vlahov, D
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (04) : 315 - 319
  • [8] Sexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy
    Melanie L. Rusch
    Homayoon Farzadegan
    Patrick M. Tarwater
    Mahboobeh Safaeian
    David Vlahov
    Steffanie A. Strathdee
    AIDS and Behavior, 2005, 9 : 289 - 299
  • [9] Sexual risk behavior among injection drug users before widespread availability of highly active antiretroviral therapy
    Rusch, ML
    Farzadegan, H
    Tarwater, P
    Safaeian, M
    Vlahov, D
    Strathdee, SA
    AIDS AND BEHAVIOR, 2005, 9 (03) : 289 - 299
  • [10] Highly active antiretroviral therapy and survival in HIV-Infected injection drug users
    Wood, Evan
    Hogg, Robert S.
    Lima, Viviane Dias
    Kerr, Thomas
    Yip, Benita
    Marshall, Brandon D. L.
    Montaner, Julio S. G.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (05): : 550 - 554